AstraZeneca granted preliminary injunction against Apotex in Pulmicort Respules patent litigation ON, MAY 20, 2009, the united states District Court for the District of NJ granted the request of AstraZeneca for an injunction barring Apotex from launching a generic edition of AstraZeneca’s Pulmicort Respules in america. No trial day for the patent litigation provides been arranged. On March 30, 2009, the united states Food and Medication Administration granted acceptance for a generic edition of AstraZeneca’s Pulmicort Respules to Apotex.Upon completion of the regimen, patients had been randomized to either constant lenalidomide or no continuous therapy until relapse. Related StoriesKey protein handles stem cell properties that will make them useful in regenerative medicineFranziska Michor named recipient of NYSCF – Robertson Stem Cell PrizeShorter individuals receive lung transplants at lower ratesFollowing the Rd induction phase, 86 percent of patients achieved a partial response or better and 37 percent accomplished at least an excellent partial response . After randomization, 55 percent of these who received at least three cycles of MPR attained at least a VGPR, with 13 percent achieving a comprehensive response .